

Title (en)
METHODS OF ADMINISTERING CAMPTOTHECIN COMPOUNDS FOR THE TREATMENT OF CANCER WITH REDUCED SIDE EFFECTS

Title (de)
VERFAHREN ZUR VERABREICHUNG VON CAMPTOTHECIN VERBINDUNGEN ZUR KREBSBEHANDLUNG MIT VERRINGERTEN NEBENWIRKUNGEN

Title (fr)
ADMINISTRATION DE COMPOSES CAMPTOTHECINIQUES DE CANCEROTHERAPIE AVEC REDUCTION DE LEURS EFFETS SECONDAIRES

Publication
EP 1003516 A4 20060712 (EN)

Application
EP 99935334 A 19990618

Priority

- US 9913906 W 19990618
- US 8978198 P 19980618

Abstract (en)
[origin: WO9965493A1] Methods of administering camptothecin compounds such as irinotecan hydrochloride to reduce a diarrhea side effect and methods of treating cancer and AIDs with camptothecin compounds including administering the camptothecin compounds while maintaining the intestinal lumen and the bile at an alkaline pH.

IPC 1-7
A61K 31/47; A61K 31/40; A61K 31/405; A61K 31/35

IPC 8 full level
C07D 491/22 (2006.01); **A61K 9/00** (2006.01); **A61K 9/107** (2006.01); **A61K 31/4745** (2006.01); **A61K 31/565** (2006.01); **A61K 31/575** (2006.01); **A61K 33/00** (2006.01); **A61K 33/10** (2006.01); **A61K 47/02** (2006.01); **A61K 47/12** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)
A61K 9/0019 (2013.01); **A61K 9/1075** (2013.01); **A61K 31/4745** (2013.01); **A61K 31/565** (2013.01); **A61K 31/706** (2013.01); **A61K 33/00** (2013.01); **A61K 33/10** (2013.01); **A61K 47/02** (2013.01); **A61K 47/12** (2013.01); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)

- [Y] WO 9606635 A1 19960307 - CORTECS LTD [GB], et al
- [Y] WO 9428911 A1 19941222 - FERRING A S [DK], et al
- [Y] WO 9611005 A2 19960418 - ATLAS LEON T [US]
- [Y] US 4294819 A 19811013 - TENCZA THOMAS M
- [YA] EP 0524579 A1 19930127 - BRISTOL MYERS SQUIBB CO [US]
- [DY] KOBAYASHI K ET AL: "UPTAKE MECHANISM OF IRINOTECAN (CPT-11) AND ITS METABOLITE (SN-38) BY HAMSTER INTESTINAL CELLS", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA., US, vol. 114, no. 4, 15 April 1998 (1998-04-15), pages A626 - A627, XP008059718, ISSN: 0016-5085
- [X] ATSUMI R ET AL: "METABOLISM OF IRINOTECAN TO SN-38 IN A TISSUE-ISOLATED TUMOR MODEL", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 18, no. 7, July 1995 (1995-07-01), pages 1024 - 1026, XP008059867, ISSN: 0918-6158
- [YA] PATENT ABSTRACTS OF JAPAN vol. 1999, no. 06 31 March 1999 (1999-03-31)
- [XPY] KOBAYASGI K. ET AL.: "Reduced Irinotecan-induced side-effects by the oral Alkalinization", PROC. AM. SOC. CLIN. ONCOL., vol. 18, no. 35, 15 May 1999 (1999-05-15), 35th annual meeting of ASCO, pages 492A, XP002370825
- [PY] MATSUZAKI Y ET AL: "CELLULAR UPTAKE AND TOXICITY OF IRINOTECAN AND ITS ACTIVE METABOLITE, SN-38 IN HAMSTER INTESTINE AND HUMAN COLON CANCER CELLS", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA., US, vol. 116, no. 4, PART 2, April 1999 (1999-04-01), pages A906, ABSTRNOG3940, XP008059942, ISSN: 0016-5085
- [PY] PATENT ABSTRACTS OF JAPAN vol. 1998, no. 13 30 November 1998 (1998-11-30)
- [A] SCOTT D O ET AL: "URINARY AND BILIARY DISPOSITION OF THE LACTONE AND CARBOXYLATE FORMS OF 20(S)-CAMPTOTHECIN IN RATS", DRUG METABOLISM AND DISPOSITION, WILLIAMS AND WILKINS., BALTIMORE, MD, US, vol. 22, no. 3, May 1994 (1994-05-01), pages 438 - 442, XP008059680, ISSN: 0090-9556
- [A] HERBEN V M M ET AL: "CLINICAL PHARMACOKINETICS OF TOPOTECAN", CLINICAL PHARMACOKINETICS, LEA & FEBIGER, PHILADELPHIA, PA, US, vol. 31, no. 2, 1996, pages 85 - 102, XP000874360
- [A] ARAKI E ET AL: "RELATIONSHIP BETWEEN DEVELOPMENT OF DIARRHEA AND THE CONCENTRATION OF SN-38, AN ACTIVE METABOLITE OF CPT-11, IN THE INTESTINE AND THE BLOOD PLASMA OF ATHYMIC MICE FOLLOWING INTRAPERITONEAL ADMINISTRATION OF CPT-11", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 84, no. 6, June 1993 (1993-06-01), pages 697 - 702, XP008059720, ISSN: 0910-5050
- [A] SCHELLENS J H M ET AL: "PHARMACOKINETICS (PK), CLINICAL PHARMACODYNAMICS (PD), AND SAFETY OF CHRONIC ORAL TOPOTECAN (T), IN A PHASE STUDY", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 31, no. 6, 1 November 1995 (1995-11-01), pages S192, ABSTRNO926, XP008059770, ISSN: 0959-8049
- See references of WO 9965493A1

Designated contracting state (EPC)
DE FR GB NL

DOCDB simple family (publication)
WO 9965493 A1 19991223; WO 9965493 A9 20000323; AU 5083399 A 20000105; AU 764370 B2 20030814; CA 2300892 A1 19991223; CN 1325305 A 20011205; EP 1003516 A1 20000531; EP 1003516 A4 20060712; IL 134592 A0 20010430; JP 2002518332 A 20020625

DOCDB simple family (application)
US 9913906 W 19990618; AU 5083399 A 19990618; CA 2300892 A 19990618; CN 99801114 A 19990618; EP 99935334 A 19990618; IL 13459299 A 19990618; JP 2000554373 A 19990618